Sozial- und Praventivmedizin · 1996
[Comparison of the efficacy of various strains of mumps vaccine: a school survey].
Сравнительное исследованиеСтатьяНазвание и аннотация: Перевод в очереди
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Toscani L, Batou M, Bouvier P, Schlaepfer A
Аннотация
BACKGROUND: Since the beginning of the program of immunization of children against measles, mumps and rubella (MMR) in 1987, various outbreaks of mumps have occurred in Switzerland, with a significant proportion of cases in immunized children. Previous studies have suggested a possible lack of efficacy of the Rubini vaccine strain, which has been much used in this country.
METHODS: Incidence study of secondary cases of mumps in the schools of Geneva, between March 18th and June 30th 1994.
STUDY POPULATION: During the study period, mumps outbreaks have been observed in 10 school classes. After exclusion of the 10 primary cases, the study population comprised 195 children aged 4 to 12 years.
RESULTS: Raw estimation of vaccine efficacy against mumps was 72.5%. Whereas both the Urabe and Jeryl-Lynn strains showed a significant efficacy, the Rubini strain didn't show any significant protective effect. After adjustment by Poisson regressions for the confounding effect of age, efficacy rates and 95% confidence limits were 75.8% (35.6%, 90.9%) for Urabe; 64.7% (10.6%, 86.0%) for Jeryl-Lynn; and 12.4% (-102%, 62.1%) für Rubini.
CONCLUSION: This study didn't show any protective effect of the Rubini vaccine strain. Furthermore, it demonstrated a statistically significant protective effect of the Urabe and Jeryl-Lynn strains, compared to the Rubini strains. In this conditions the use of the Rubini strain should be restricted to situations of confirmed contra-indications to the other vaccinal strains, as long as its protective efficacy is not clearly demonstrated.
METHODS: Incidence study of secondary cases of mumps in the schools of Geneva, between March 18th and June 30th 1994.
STUDY POPULATION: During the study period, mumps outbreaks have been observed in 10 school classes. After exclusion of the 10 primary cases, the study population comprised 195 children aged 4 to 12 years.
RESULTS: Raw estimation of vaccine efficacy against mumps was 72.5%. Whereas both the Urabe and Jeryl-Lynn strains showed a significant efficacy, the Rubini strain didn't show any significant protective effect. After adjustment by Poisson regressions for the confounding effect of age, efficacy rates and 95% confidence limits were 75.8% (35.6%, 90.9%) for Urabe; 64.7% (10.6%, 86.0%) for Jeryl-Lynn; and 12.4% (-102%, 62.1%) für Rubini.
CONCLUSION: This study didn't show any protective effect of the Rubini vaccine strain. Furthermore, it demonstrated a statistically significant protective effect of the Urabe and Jeryl-Lynn strains, compared to the Rubini strains. In this conditions the use of the Rubini strain should be restricted to situations of confirmed contra-indications to the other vaccinal strains, as long as its protective efficacy is not clearly demonstrated.